Search
forLearn
5 / 801 resultslearn TDM-105795
learn D-Pantothenyl Alcohol
learn sh-Polypeptide-7
learn PTT-6®
Research
5 / 1000+ results
research Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia
New treatments for hair loss show promise but need more testing for effectiveness and safety.
research Diphencyprone Induced Vitiligo: A Case Report
Diphencyprone can cause unexpected and possibly permanent vitiligo.
research The use of diphencyprone in dermatology: A retospective audit
Diphencyprone treatment protocols could be simplified as no harm occurred despite not fully following them.
research 557 A peptide derivative with known anti-wrinkle properties was identified as potent dipeptiylpeptidase-4 inhibitor
A peptide known for reducing wrinkles also effectively inhibits an enzyme linked to skin inflammation and acne.
research Monovalent antibody-conjugated lipid-polymer nanohybrids for active targeting to desmoglein 3 of keratinocytes to attenuate psoriasiform inflammation
The targeted nanohybrids effectively reduced psoriasis symptoms and improved skin health.
Community Join
5 / 73 resultscommunity VDPHL-01 is Overrated and Ridiculous. This is just Oral Minoxidil.
VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.
community VDPHL01 phase-2/3 results comparison
The conversation discusses hair loss treatments, focusing on a new slow-release oral minoxidil compared to topical minoxidil and finasteride. The results show that twice-daily dosing of the new treatment is slightly more effective than once-daily, but concerns about cost, side effects, and the accuracy of reported results remain.
community VDPHL01 works really quickly .. apparently?
VDPHL01 shows faster and stronger hair growth compared to standard minoxidil, with no major side effects reported. Users discuss combining it with other treatments like dutasteride and finasteride for better results, while expressing skepticism about the effectiveness of PP405.
community Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Veradermics is working on FDA approval for extended-release oral Minoxidil. Approval is expected around 2027.
community Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.